CG
CRMD icon

Castellan Group’s CorMedix CRMD Stock Holding History

Castellan Group’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-32,500
Closed -$123K – 64
2023
Q4 		$123K Buy
32,500
+2,500
+8% +$8.6K 0.08% 57
2023
Q3 		$111K Buy
30,000
+5,200
+21% +$20.7K 0.08% 60
2023
Q2 		$98.3K Buy
+24,800
New +$123K 0.06% 62

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Castellan Group's CRMD Position: Q1 2024 in Review

Castellan Group sold out of CorMedix (CRMD) in Q1 2024, closing a stake of 32,500 shares — an estimated $123K sold.

Castellan Group first reported a position in CRMD in Q2 2023 and held it in 3 quarters. The position peaked at $123K in Q4 2023. 91 funds tracked by Wall St. Rank hold CRMD as of Q1 2024.

  • Castellan Group reported no remaining CorMedix position as of Q1 2024 after selling out during the quarter.
  • Castellan Group sold 32,500 CorMedix shares in Q1 2024, an estimated $123K.
  • Castellan Group first reported a position in CorMedix in Q2 2023 and held it in 3 quarters.
  • Castellan Group's CorMedix position peaked at $123K in Q4 2023.
  • 91 funds tracked by Wall St. Rank held CorMedix as of Q1 2024.

Based on Castellan Group's 13F filing for Q1 2024, filed 15 May 2024.